IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v10y2019i1d10.1038_s41467-019-13315-x.html
   My bibliography  Save this article

The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status

Author

Listed:
  • Ricky M. Trigg

    (University of Cambridge
    Medicinal Science & Technology)

  • Liam C. Lee

    (University of Cambridge
    Amgen)

  • Nina Prokoph

    (University of Cambridge)

  • Leila Jahangiri

    (University of Cambridge)

  • C. Patrick Reynolds

    (Cancer Center, Texas Tech University Health Sciences Center School of Medicine)

  • G. A. Amos Burke

    (Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus)

  • Nicola A. Probst

    (University of Cambridge)

  • Miaojun Han

    (University of Cambridge
    OncoSec)

  • Jamie D. Matthews

    (University of Cambridge)

  • Hong Kai Lim

    (University of Cambridge)

  • Eleanor Manners

    (University of Cambridge)

  • Sonia Martinez

    (Spanish National Cancer Research Centre (CNIO))

  • Joaquin Pastor

    (Spanish National Cancer Research Centre (CNIO))

  • Carmen Blanco-Aparicio

    (Spanish National Cancer Research Centre (CNIO))

  • Olaf Merkel

    (Medical University of Vienna)

  • Ines Garces los Fayos Alonso

    (Medical University of Vienna)

  • Petra Kodajova

    (University of Veterinary Medicine Vienna)

  • Simone Tangermann

    (University of Veterinary Medicine Vienna)

  • Sandra Högler

    (University of Veterinary Medicine Vienna)

  • Ji Luo

    (National Cancer Institute, National Institutes of Health)

  • Lukas Kenner

    (Medical University of Vienna
    University of Veterinary Medicine Vienna
    Medical University of Vienna)

  • Suzanne D. Turner

    (University of Cambridge)

Abstract

Resistance to anaplastic lymphoma kinase (ALK)-targeted therapy in ALK-positive non-small cell lung cancer has been reported, with the majority of acquired resistance mechanisms relying on bypass signaling. To proactively identify resistance mechanisms in ALK-positive neuroblastoma (NB), we herein employ genome-wide CRISPR activation screens of NB cell lines treated with brigatinib or ceritinib, identifying PIM1 as a putative resistance gene, whose high expression is associated with high-risk disease and poor survival. Knockdown of PIM1 sensitizes cells of differing MYCN status to ALK inhibitors, and in patient-derived xenografts of high-risk NB harboring ALK mutations, the combination of the ALK inhibitor ceritinib and PIM1 inhibitor AZD1208 shows significantly enhanced anti-tumor efficacy relative to single agents. These data confirm that PIM1 overexpression decreases sensitivity to ALK inhibitors in NB, and suggests that combined front-line inhibition of ALK and PIM1 is a viable strategy for the treatment of ALK-positive NB independent of MYCN status.

Suggested Citation

  • Ricky M. Trigg & Liam C. Lee & Nina Prokoph & Leila Jahangiri & C. Patrick Reynolds & G. A. Amos Burke & Nicola A. Probst & Miaojun Han & Jamie D. Matthews & Hong Kai Lim & Eleanor Manners & Sonia Mar, 2019. "The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status," Nature Communications, Nature, vol. 10(1), pages 1-13, December.
    • Handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-13315-x
    DOI: 10.1038/s41467-019-13315-x
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-019-13315-x
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-019-13315-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Karin Schmelz & Joern Toedling & Matt Huska & Maja C. Cwikla & Louisa-Marie Kruetzfeldt & Jutta Proba & Peter F. Ambros & Inge M. Ambros & Sengül Boral & Marco Lodrini & Celine Y. Chen & Martin Burker, 2021. "Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions," Nature Communications, Nature, vol. 12(1), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-13315-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.